October 2, 2008 - DNA Direct Inc. said it will offer ColoSure, a reportedly simple test to screen for colon cancer.
ColoSure tests a single stool sample for a DNA marker associated with colorectal cancer. ColoSure is reportedly the first clinical test available that looks for a DNA change in the vimentin gene, shown to be important to immunity and other important cell processes in the body. If the vimentin gene is hyper-methylated, or “turned off,” this could indicate colon cancer. A study published in the September 2008 issue of the American Journal of Gastroenterology shows that detecting methylated vimentin DNA in feces provided both high sensitivity (77 percent) and high specificity (83 percent) for detecting early-stage, curable colon cancers.
DNA Direct’s personalized, Web-enabled report for recipients of the ColoSure test includes an overview of test results, a lab report and letter to bring to their physician, and recommended next steps. Reports also reinforce awareness of the signs and symptoms of colorectal cancer, and include an option to schedule a reminder for the patient’s next screening. Finally, the report includes a section on how ColoSure works, ways to change contributing lifestyle factors, a list of resources for patients and important facts about colorectal cancer.
For more information: www.dnadirect.com
October 30, 2026 
